Technetium-99m-Sestamibi (99mTc-sestamibi) scintigraphy has been shown to be capable of differentiating patients with multiple myeloma (MM) in remission from those with active disease.1-10 We studied 5 patients with MM (2 females and 3 males, age 53±17 years) before and after treatment. 99mTc-sestamibi scintigraphic results were concordant with clinical status.
Technetium-99m Sestamibi Scintigraphy in Monitoring Patients with Multiple Myeloma
PACE, Leonardo
2000
Abstract
Technetium-99m-Sestamibi (99mTc-sestamibi) scintigraphy has been shown to be capable of differentiating patients with multiple myeloma (MM) in remission from those with active disease.1-10 We studied 5 patients with MM (2 females and 3 males, age 53±17 years) before and after treatment. 99mTc-sestamibi scintigraphic results were concordant with clinical status.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
